Galectin-9 Inhibits Glomerular Hypertrophy in db/db Diabetic Mice via Cell-Cycle–Dependent Mechanisms
Authors:
- Jun WadaJWJun Wada
- Jun EguchiJEJun Eguchi
- Izumi HashimotoIHIzumi Hashimoto
- Tatsuo OkadaTOTatsuo Okada
- Akihiro YasuharaAYAkihiro Yasuhara
- Kenichi ShikataKSKenichi Shikata
- Yashpal S. KanwarYKYashpal S. Kanwar
- Hirofumi MakinoHMHirofumi Makino
Open Access
- 1 November 2005
- journal article
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 16 (11) , 3222-3234
Abstract
Galectins are β-galactoside–binding lectins that are involved in various biologic processes, such as apoptosis, cell proliferation, and cell-cycle regulation. Galectin-9 (Gal-9) was identified previously and demonstrated to have apoptotic potential to thymocytes in mice and activated CD8+ T cells in nephrotoxic serum nephritis model. In this study, the effect of Gal-9 on G1-phase cell-cycle arrest, one of the hallmark pathologic changes in early diabetic nephropathy, was investigated. Eight-week-old male db/db mice received injections of recombinant Gal-9 or vehicle for 8 wk. The injection of Gal-9 into db/db mice significantly inhibited glomerular hypertrophy and mesangial matrix expansion and reduced urinary albumin excretion. Gal-9 reduced glomerular expression of TGF-β1 and the number of p27Kip1- and p21Cip1-positive cells in glomeruli. Double staining with nephrin and type IV collagen revealed that podocytes were mainly positive for p27Kip1. For further confirming the cell-cycle regulation by Gal-9, conditionally immortalized mouse podocyte cells were cultured under 5.5 and 25 mM d-glucose supplemented with Gal-9. Cell-cycle distribution analyses revealed that Gal-9 maintained further progression of cell cycle from the G1 phase. Gal-9 reversed the high-glucose–mediated upregulation of p27Kip1 and p21Cip1 and inhibited cell-cycle–dependent hypertrophy, i.e., reduced [3H]proline incorporation. The data suggest that Gal-9 plays a central role in inducing their successful progression from G1 to G2 phase by suppressing glomerular expression of TGF-β1 and inhibition of cyclin-dependent kinase inhibitors. Gal-9 may give an impetus to develop new therapeutic tools targeted toward diabetic nephropathy.Keywords
This publication has 52 references indexed in Scilit:
- Galectin-12 Is Required for Adipogenic Signaling and Adipocyte DifferentiationJournal of Biological Chemistry, 2004
- p27Kip1Journal of the American Society of Nephrology, 2003
- Role of galectins in inflammatory and immunomodulatory processesBiochimica et Biophysica Acta (BBA) - General Subjects, 2002
- Possible role of galectin‐9 in cell aggregation and apoptosis of human melanoma cell lines and its clinical significanceInternational Journal of Cancer, 2002
- Cell Cycle Regulation by Galectin-12, a New Member of the Galectin SuperfamilyJournal of Biological Chemistry, 2001
- Laser scanning cytometry (LCS) allows detailed analysis of the cell cycle in PI stained human fibroblasts (TIG‐7)Cell Proliferation, 1997
- Biphasic modulation of cell growth by recombinant human galectin-1Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1996
- Evidence That the Diabetes Gene Encodes the Leptin Receptor: Identification of a Mutation in the Leptin Receptor Gene in db/db MiceCell, 1996
- Apoptosis of T cells mediated by galectin-1Nature, 1995
- Galectins: A family of animal β-galactoside-binding lectinsCell, 1994